Ipsen to divest consumer health unit, focus on speciality care

11 February 2022
france_big

Ipsen (Euronext: IPN) has reported annual revenues of 2.87 billion euros ($3.3 billion), falling just short of the FT consensus forecast of 2.9 billion euros.

The annual figure was up 10.7% from 2020, which saw sales of 2.6 billion euros. For the final quarter, Ipsen booked revenues of 791 million euros, up 14.6% quarter-on-quarter.

Net profit was up 24% in 2021, at 758 million euros, resulting in earnings per share (EPS) of 9.09 euros.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical